Concord Biotech Limited CONCORDBIO.NS · Stock Open Concord Biotech Limited in new tab
Concord Biotech Limited Analysis (CONCORDBIO.NS)
Is Concord Biotech Limited a good investment? Concord Biotech Limited (CONCORDBIO.NS) is currently trading at 1420.00 INR. Market analysts have a consensus price target of 1216.00 INR. This suggests the asset is currently trading above analyst expectations.
In terms of valuation, the stock trades at a P/E ratio of 48.81. This high multiple suggests investors have priced in significant future growth expectations.
Earnings Schedule: Concord Biotech Limited is expected to release its next earnings report on Aug. 7, 2026. The market consensus estimate for Forward EPS is 41.05.
For income investors, Concord Biotech Limited pays a dividend yield of 0.57%. With a payout ratio of 43%, the dividend appears sustainable.
Investor FAQ
Does Concord Biotech Limited pay a dividend?
Yes, it pays an annual dividend of 7.55 INR (0.57% yield).
What asset class is Concord Biotech Limited?
Concord Biotech Limited is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 7, 2026. The company currently has a trailing EPS of 28.98.
Company Profile
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
| Year | Total Dividends |
|---|---|
| ▸2026 |
18.25 INR
|
| Oct. 9, 2026 (estimated) | 10.7000 |
| Aug. 30, 2026 | 7.5500 |
| ▸2025 |
10.70 INR
|
| Oct. 9, 2025 | 10.7000 |
| ▸2024 |
8.75 INR
|
| July 29, 2024 | 8.7500 |
| Name | Payment Date | Status | Amount |
|---|---|---|---|
| Concord Biotech Limited | Aug 30, 2026 | Upcoming | 7.55 INR |
| Concord Biotech Limited | Oct 09, 2025 | Paid | 10.7 INR |
Community Discussion